Drug Approval | November 10, 2024
Granules India’s Unit V facility secures USFDA EIR with NAI status
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
Subscribe To Our Newsletter & Stay Updated
